Syncom Formulations (India) Ltd: Is It a Deep Value Opportunity?

Syncom Formulations (India) Ltd has a deep value score of 50/100 (rated Average). This score is calculated from three components

• Earnings Score: 30/40 — measures PAT growth momentum across quarters
• Underperformance Score: 14/35 — how much the stock trails Nifty 500 (deeper underperformance = higher contrarian signal)
• Quality Score: 9/25 — operational quality (margins, revenue growth, valuation)

Syncom Formulations (India) Ltd's quarterly profit (PAT) growth trajectory

• Latest Quarter PAT Growth (QoQ): +33%
• Previous Quarter PAT Growth (QoQ): +14%
• 2 Quarters Ago PAT Growth (QoQ): +5%
• PAT Acceleration: +13.9pp (profits are accelerating)
• 3 consecutive quarters of positive PAT growth

Syncom Formulations (India) Ltd is underperforming the market despite improving earnings — this is the core deep value thesis

• 1-Year Return vs Nifty 500: -25%
• 6-Month Return vs Nifty 500: +8%
• 3-Month Return vs Nifty 500: 0%
• Yet average quarterly PAT growth is +17% — earnings are improving
• The market often takes time to re-rate stocks with improving fundamentals. This gap between price performance and earnings improvement is what deep value research seeks to identify.

Syncom Formulations (India) Ltd's earnings momentum is Steady — consistent growth.

• PAT QoQ progression: +5% → +14% → +33% (2Q ago → 1Q ago → latest)
• Acceleration: +13.9pp
• PAT YoY Growth: +39%

Syncom Formulations (India) Ltd's valuation metrics

• Price-to-Earnings (PE): 16.4x
• Price-to-Book (PB): 3.2x
• PEG Ratio: 0.3x
• Margin of Safety: +6% (appears fairly valued)

Syncom Formulations (India) Ltd's revenue and margin trends

• Latest Quarter Revenue Growth (QoQ): +18%
• Average Quarterly Revenue Growth: +5%
• Revenue Acceleration: +6.7pp
• Latest OPM Change: -2.2pp (margins contracting)
• Average OPM Change: +0.9pp
• Revenue YoY: -9%

Syncom Formulations (India) Ltd's trailing twelve month (TTM) performance

• TTM PAT: ₹77 Cr
• TTM PAT Growth: +54.0% YoY
• TTM Revenue: ₹489 Cr
• TTM Revenue Growth: +4.9% YoY
• TTM Operating Margin: 15.7%

Syncom Formulations (India) Ltd key facts

• Sector: Pharma - Others
• Market Cap: ₹1.3K Cr
• Rank in Pharma - Others: #2 by value score
• Overall rank among all deep value stocks: #64

Syncom Formulations (India) Ltd shows limited deep value signals currently — score is 50/100 (Average). Monitor for improvement.

• Value Score: 50/100 (Average)
• Earnings: Accelerating
• 1Y Underperformance: -25% vs Nifty 500

Other deep value stocks in Pharma - Others

• TTK Healthcare Ltd — Score 49/100, Average, earnings accelerating

Pharma - Others deep value sector overview

• 2 deep value stocks in this sector
• Average value score: 50/100
• Avg PAT acceleration: +19.4pp
• Top pick: TTK Healthcare Ltd

Deep value investing studies stocks that are underperforming the market despite showing improving fundamentals. The thesis is that the market has not yet recognized the earnings recovery, creating a potential valuation gap. It requires patience — recovery can take several quarters.

The deep value score (0-100) combines three factors:

- Earnings (0-40 pts): PAT growth across last 3 quarters, acceleration, and consecutive growth - Underperformance (0-35 pts): How much the stock trails Nifty 500 over 1Y, 6M, 3M (deeper underperformance = higher score) - Quality (0-25 pts): Revenue growth, margin trends, and valuation metrics (PEG, P/B)

Higher score indicates a stronger contrarian research signal.